Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Sino Biopharm strikes licensing and distribution deals with AstraZeneca and GSK

Sino Biopharm granted AstraZeneca exclusive rights for the inhaled PDE3/4 inhibitor TQC3721 outside China, agreeing to an upfront payment of 200 million USD, milestone payments of up to 1.9 billion USD and tiered double-digit royalties. At the same time, the company expanded its partnership with GSK and secured commercialization rights for Trelegy Ellipta and Anoro Ellipta in mainland China; Sino Biopharm will handle import, distribution, hospital access and promotion and will record the revenues in China. The stock then rose by as much as 7% and later gave back some of the gains. » More on de.investing.com
Sino Biopharm to pursue more biotech acquisitions and multinational partnerships

Chairwoman Theresa Tse said Sino Biopharm remains open to buying more Chinese biotech companies following a recent acquisition and is seeking partnerships with larger multinational firms. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sino Biopharma has already paid €0.0134 in dividends. The last payout was in September.

Financials

In the last quarter, Sino Biopharma had revenue of €1.25bn and net profit of €221.48m

(EUR)	June 2026	YoY
Revenue	1.25bn	20.49%
Gross profit	1.04bn	21.33%
Net profit	221.48m	10.38%
EBITDA	461.53m	95.63%

Fundamentals

Metric	Value
Market capitalization	€10.56bn
Number of shares	17.81bn
52-week high/low	€0.79 - €0.53
Dividend yield	2.36%
Dividends TTM	€0.0134
Beta	0.61
P/E ratio	32.09
PEG ratio	-0.78
P/B ratio	2.37
P/S ratio	2.25

Company profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Name	Sino Biopharma
CEO	S. Y. Tse
Headquarters	Hong Kong, China
Website	sinobiopharm.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	12/05/2004
Employees	21,435